Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Samsung Biologics Co.,Ltd.

Samsung Biologics provides contract development and manufacturing organization (CDMO) services for biopharmaceuticals, including development, manufacturing, and quality services, self-described as a leading global CDMO.

msh id	COM:SAMSUNGBIOLOGICS
symbol	207.94K
name	Samsung Biologics Co.,Ltd.
homepage url	https://samsungbiologics.com
country	KR
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	4.28K
crunchbase url	-
linkedin url	-
founders	-

market cap	41.91B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.28
growth cost of revenue	0.23
growth depreciation and amortization	0.26
growth ebitda	0.23
growth ebitda ratio	0
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.19
growth gross profit	0.23
growth gross profit ratio	-0

COM:SAMSUNGBIOLOGICS

Samsung Biologics

Last Close

932K

22/11 05:20

Market Cap

58.01T

Beta: -

Volume Today

36.79K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	1.89B
cost of revenue	1.89B
depreciation and amortization	358.22M
ebitda	1.24B
ebitda ratio	0.46
eps	8.81
eps diluted	8.81
operating expenses	1.89B
operating income	814.54M
operating income ratio	0.3

accounts receivables	-11.39M
capital expenditure	-808.43M
cash at beginning of period	651.54M
cash at end of period	269.11M
inventory	1.93B
working capital ttm	1.32T

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-